245 related articles for article (PubMed ID: 22449622)
21. Eosinophilia: secondary, clonal and idiopathic.
Tefferi A; Patnaik MM; Pardanani A
Br J Haematol; 2006 Jun; 133(5):468-92. PubMed ID: 16681635
[TBL] [Abstract][Full Text] [Related]
22. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders.
Valent P
Blood Rev; 2009 Jul; 23(4):157-65. PubMed ID: 19246139
[TBL] [Abstract][Full Text] [Related]
23. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
Shomali W; Gotlib J
Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
[TBL] [Abstract][Full Text] [Related]
24. Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Tefferi A; Gotlib J; Pardanani A
Mayo Clin Proc; 2010 Feb; 85(2):158-64. PubMed ID: 20053713
[TBL] [Abstract][Full Text] [Related]
25. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
Lierman E; Cools J
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
[TBL] [Abstract][Full Text] [Related]
26. Modern diagnosis and treatment of primary eosinophilia.
Tefferi A
Acta Haematol; 2005; 114(1):52-60. PubMed ID: 15995325
[TBL] [Abstract][Full Text] [Related]
27. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2012 Sep; 87(9):903-14. PubMed ID: 22926771
[TBL] [Abstract][Full Text] [Related]
28. Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia.
Kahn JE; Dutoit-Lefevre V; Duban-Deweer S; Chafey P; Pottiez G; Lefranc D; Fain O; Cordier JF; Hatron PY; Bletry O; Prin L
J Proteome Res; 2011 Apr; 10(4):1468-80. PubMed ID: 21302907
[TBL] [Abstract][Full Text] [Related]
29. Atypical myeloproliferative disorders: diagnosis and management.
Tefferi A; Elliott MA; Pardanani A
Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
[TBL] [Abstract][Full Text] [Related]
30. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.
Tefferi A; Gilliland G
Best Pract Res Clin Haematol; 2006; 19(3):365-85. PubMed ID: 16781478
[TBL] [Abstract][Full Text] [Related]
31. Primary eosinophilic disorders: a concise review.
Pardanani A; Tefferi A
Curr Hematol Malig Rep; 2008 Jan; 3(1):37-43. PubMed ID: 20425445
[TBL] [Abstract][Full Text] [Related]
32. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW
Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
[TBL] [Abstract][Full Text] [Related]
33. [Review of changes introduced by the new WHO classification (4th edition) of myeloid neoplasms. An overview].
Komatsu N
Rinsho Ketsueki; 2009 Mar; 50(3):127-33. PubMed ID: 19352078
[No Abstract] [Full Text] [Related]
34. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.
Bain BJ
Br J Haematol; 1996 Oct; 95(1):2-9. PubMed ID: 8857931
[TBL] [Abstract][Full Text] [Related]
35. Genomic analysis of clonal eosinophils by CGH arrays reveals new genetic regions involved in chronic eosinophilia.
Arefi M; Robledo C; Peñarrubia MJ; García de Coca A; Cordero M; Hernández-Rivas JM; García JL
Eur J Haematol; 2014 Nov; 93(5):422-8. PubMed ID: 24813417
[TBL] [Abstract][Full Text] [Related]
36. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
37. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
[TBL] [Abstract][Full Text] [Related]
38. [Myeloproliferative neoplasms and related diseases].
Kirito K
Rinsho Ketsueki; 2009 Mar; 50(3):134-46. PubMed ID: 19352079
[No Abstract] [Full Text] [Related]
39. Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.
Rathe M; Kristensen TK; Møller MB; Carlsen NL
Pediatr Blood Cancer; 2010 Oct; 55(4):730-2. PubMed ID: 20589620
[TBL] [Abstract][Full Text] [Related]
40. Idiopathic hypereosinophilic syndrome and "eosinophilic leukemia".
Cassi E; De Paoli A; Fava S; Luoni M; Tosi A; Turri C; Grimi E
Haematologica; 1992; 77(5):430-2. PubMed ID: 1483595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]